期刊文献+

MEK1在结直肠癌中表达及临床意义的研究(英文)

Expression of MEK1 in the colorectal cancer and its clinical implication
下载PDF
导出
摘要 Objective:The aim of this study was to investigate the relationship between expression of MEK1 protein in the mitogen-activated protein kinase (MAPK) signaling pathway and liver as well as lymph node metastasis in colorectal cancer patients.Methods:Immunohistochemistry was performed to detect the expression of MEK1 protein in primary cancer,normal colonic mucosa,lymph nodes and liver metastatic foci from 86 colorectal cancer patients.Life table analysis was employed to evaluate the association between MEK1 expression and patients' survival.Results:The positive rate of MEK1 expression in the primary cancer,normal colonic mucosa,metastatic lymph nodes and liver metastatic foci was 52.3%,32.6%,71.4% and 78.3%,respectively.The positive rate of MEK1 expression in the primary cancer,metastatic lymph nodes and liver metastatic foci was significantly higher than that in the normal colonic mucosa (P < 0.01).Furthermore,the positive rate of MEK1 expression in stage III and IV colorectal cancer patients was dramatically higher than that in stage I and II colorectal cancer patients (P < 0.01).The positive rate of MEK1 expression in patients with poorly differentiated adenocarcinoma and mucinous adenocarcinoma was significantly higher than patients with well or moderately differentiated adenocarcinoma (P < 0.01).The 3-year disease-free survival rate was 41.3% in MEK1 positive patients and 73.1% in MEK1 negative patients.The survival rate of MEK1 positive patients was significantly lower than that of MEK1 negative patients (P < 0.05).Conclusion:The increased expression of MEK1 was associated with lymph node metastasis and liver metastasis of colorectal cancer.Therefore,detection of MEK1 expression may have important significance in the evaluation of patients' prognosis. Objective:The aim of this study was to investigate the relationship between expression of MEK1 protein in the mitogen-activated protein kinase (MAPK) signaling pathway and liver as well as lymph node metastasis in colorectal cancer patients.Methods:Immunohistochemistry was performed to detect the expression of MEK1 protein in primary cancer,normal colonic mucosa,lymph nodes and liver metastatic foci from 86 colorectal cancer patients.Life table analysis was employed to evaluate the association between MEK1 expression and patients' survival.Results:The positive rate of MEK1 expression in the primary cancer,normal colonic mucosa,metastatic lymph nodes and liver metastatic foci was 52.3%,32.6%,71.4% and 78.3%,respectively.The positive rate of MEK1 expression in the primary cancer,metastatic lymph nodes and liver metastatic foci was significantly higher than that in the normal colonic mucosa (P 〈 0.01).Furthermore,the positive rate of MEK1 expression in stage III and IV colorectal cancer patients was dramatically higher than that in stage I and II colorectal cancer patients (P 〈 0.01).The positive rate of MEK1 expression in patients with poorly differentiated adenocarcinoma and mucinous adenocarcinoma was significantly higher than patients with well or moderately differentiated adenocarcinoma (P 〈 0.01).The 3-year disease-free survival rate was 41.3% in MEK1 positive patients and 73.1% in MEK1 negative patients.The survival rate of MEK1 positive patients was significantly lower than that of MEK1 negative patients (P 〈 0.05).Conclusion:The increased expression of MEK1 was associated with lymph node metastasis and liver metastasis of colorectal cancer.Therefore,detection of MEK1 expression may have important significance in the evaluation of patients' prognosis.
出处 《The Chinese-German Journal of Clinical Oncology》 CAS 2012年第3期142-145,共4页 中德临床肿瘤学杂志(英文版)
基金 Supported by agrant from the National Natural Science Foundation of China (No. 81101860)
  • 相关文献

参考文献8

  • 1Fang JY,Richardson BC.The MAPK signalling pathways and colorectal cancer.Lancet Oncol,2005,6:322-327.
  • 2Gout S,Morin C,Houle F,et al.Death receptor-3,a new E-selectin counter-receptor that confers migration and survival advantages to colon carcinoma cells by triggering p38 and ERK MAPK activation.Cancer Res,2006,66:9117-9124.
  • 3Deng H,Ravikumar TS,Yang WL.Bone morphogenetic protein-4 inhibits heat-induced apoptosis by modulating MAPK pathways in human colon cancer HCT116 cells.Cancer Lett,2007,256:207-217.
  • 4Yasuda A,Sawai H,Takahashi H,et al.Stem cell factor/c-kit receptor signaling enhances the proliferation and invasion of colorectal cancer cells through the PI3K/Akt pathway.Dig Dis Sci,2007,52:2292-2300.
  • 5Tshuchiya T,Tsuno NH,Asakage M,et al.Apoptosis induction by p38 MAPK inhibitor in human colon cancer cells.Hepatogastroenterology,2008,55:930-935.
  • 6Benvenuti S,Sartore-Bianchi A,Di Nicolantonio F,et al.Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.Cancer Res,2007,67:2643-2648.
  • 7Shama J,Garcia-Mediana R,Pouysségur J,et al.Major contribution of MEK1 to the activation of ERK1/ERK2 and to the growth of LS174T colon carcinoma cells.Biochem Biophys Res Commun,2008,372:845-849.
  • 8Leicht DT,Balan V,Kaplun A,et al.Raf kinases:function,regulation and role in human cancer.Biochim Biophys Acta,2007,1773:1196-1212.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部